NYMOX PHARMACEUTICAL CORPORATION
NASDAQ : NYMX

NYMOX PHARMACEUTICAL CORPORATION

June 08, 2005 09:48 ET

Nymox Reports Positive New Data for BPH Drug

MAYWOOD, N.J.--(CCNMatthews - Jun 8, 2005) -

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today new longer term follow-up results from Phase 1-2 testing of NX-1207, the Company's investigational new drug for benign prostatic hyperplasia (BPH). The trial data indicated that at 18-23 months' follow-up, there was symptomatic improvement and no safety issues in individuals treated with NX-1207. The symptomatic improvement with NX-1207 at this longer term follow-up reached statistical significance.

"These are exciting results," said Paul Averback, MD, CEO of Nymox, "NX-1207 now has shown statistical significance in clinical improvement measures at up to 23 months. The potential for long term improvement in BPH from NX-1207 now has Phase 2 data to support it."

Dr. Averback added, "We will be providing further clinical details on these findings at a later date. We are also anticipating other new trial data later in 2005 from the large currently ongoing multicenter trial of NX-1207."

Patients in the trial of NX-1207 who were available for follow-up were administered AUA Symptom Score evaluations after periods of 18-23 months post treatment. The mean AUA score in patients treated with NX-1207 showed a 9.3 point improvement compared to controls. This reached statistical significance and exceeded results from the Phase 1-2 30 day study of NX-1207 reported by Nymox earlier in 2004. In the latter study there was a 6.9 point improvement in AUA score. Subjects followed up after one year also showed a statistically significant improvement of 8.8 points compared to controls.

The AUA BPH symptom score measurement includes data on 1) sensations of incomplete emptying of the bladder; 2) need to urinate frequently; 3) stopping and starting during urination; 4) urgent need to urinate; 5) weakness of urinary stream; 6) need to push or strain during urination; and 7) urination during sleep (nocturia).

There was no significant adverse side effects from NX-1207 in these trials.

BPH afflicts approximately half of men over age 50 and close to 90% of men by age 80. The disorder causes difficulties with urination associated with aging, such as urination at night, urge to void frequently, hesitancy, weak stream, and other problems.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The conduct of clinical trials and the development of drug products involve substantial risks and uncertainties and actual results may differ materially from expectations. Promising early results do not ensure that later stage or larger scale clinical trials will be successful or will proceed as expected. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information

  • Nymox Pharmaceutical Corporation
    Roy Wolvin, 1-800-93NYMOX
    website: www.nymox.com